Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Latest Information Update: 18 Jan 2023
At a glance
- Drugs Atezolizumab (Primary) ; RG 6146 (Primary)
- Indications Advanced breast cancer; Ovarian cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech; Roche
- 05 Apr 2022 Status changed from discontinued to completed.
- 10 Apr 2021 Results presented at the 112th Annual Meeting of the American Association for Cancer Research
- 09 Jul 2019 Status changed from suspended to discontinued.